Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh, +8

The Lancet

Iressa Survival EvaluationMedicineCancer ManagementBronchial NeoplasmCancer Treatment +4

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn, +16

Journal of Clinical Oncology

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell, +19

The Lancet Oncology

OncologyMedicineMetronomic TherapyClinical TrialsPharmacotherapy +6

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R. Hirsch, Alexander Luft, +17

The Lancet Oncology

First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCisplatin Versus Gemcitabine +5

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

Lucio Crinò, Éric Dansin, Pilar Garrido, +8

The Lancet Oncology

MedicinePhase 4First-line Bevacizumab-based TherapyImmune Checkpoint InhibitorCancer Treatment +3

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Mark A. Socinski, Egbert F. Smit, Paul Lorigan, +15

Journal of Clinical Oncology

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Giuseppe Giaccone, Mariëlle Gallegos Ruiz, Thierry Le Chevalier, +6

Clinical Cancer Research

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Alex Y. Chang, Purvish M. Parikh, Sumitra Thongprasert, +8

Journal of Thoracic Oncology

Isel StudyOncologyAsian OriginPathologyBronchial Neoplasm +5

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Luis Paz‐Ares, J. Mezger, Tudor–Eliade Ciuleanu, +22

The Lancet Oncology

First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCancer Treatment +4

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Alex Y. Chang, Purvish M. Parikh, Sumitra Thongprasert, +8

Journal of Thoracic Oncology

Isel StudyOncologyAsian OriginPathologyBronchial Neoplasm +5